Evaxion Biotech will present its work on the core of AI-immunology
COPENHAGEN, Denmark, October 12, 2021 (GLOBE NEWSWIRE) – Evaxion Biotech A / S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in developing immunotherapies to improve lives patients with cancer, bacterial diseases and viral infections, today announced a presentation by Emma Christine Jappe, PhD, Senior Scientist, Research and Development, at the Immuno UK conference to be held in London on the 13th and October 14, 2021.
The presentation, titled “AI-Based Methods to Decode the Immune System and Improve the Design of Immunotherapy in Cancer,” will introduce Evaxion’s core AI-immunology technology and detail how the company uses the AI to decode the immune system.
Dr Jappe will focus on PIONEER, Evaxion’s proprietary AI platform to identify patient-specific neoepitopes used to develop cancer immunotherapies, and demonstrate how Evaxion is continuously working to improve this platform through the generation of immunological data and the development of optimized AI models.
As part of the presentation, Dr Jappe will also explain how Evaxion studies additional features of neoepitope binding to specialized immune molecules called MHCs, and discuss a new method developed by Evaxion to demonstrate that the biological characteristic of stability thermal of peptide-MHC improves. neoepitope prediction. This work, entitled “Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design”, was published in Nature Communication end of 2020.
The details of the presentation are as follows:
- Wednesday, October 13, 2021 at 10:40 a.m. BST
- To register for the event click here
Evaxion Biotech A / S is a clinical stage IA-Immunology ™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI immunology core technology, Evaxion is developing a broad portfolio of new product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in phase 1 / 2a of clinical development. In addition, Evaxion is developing a portfolio of vaccines to prevent bacterial and viral infections currently in preclinical development.
Source: Evaxion Biotech
This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this announcement regarding the operations, plans and future objectives of the Company are forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement regarding future events are subject to (i) change without notice and (ii) factors beyond the control of the Company. These statements may include, but are not limited to, statements preceded, followed or including words such as “target”, “believe”, “expect”, “hope”, “aim”, “intend” of “,” can “,” “could”, “anticipate”, “consider”, “continue”, “estimate”, “plan”, “potential”, “foresee”, “plan”, “want”, “can have “,” probably “,” should, “” would, “” could, “and other words and terms with similar or negative meanings thereof. Actual results may differ materially from those indicated by such forward-looking statements. due to various factors including, but not limited to: risks associated with the financial condition of the Company and the need for additional capital; risks associated with the development work of the Company; cost and success of operations product development and preclinical and clinical trials of the Company; risks related to the commercialization any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties, including for the conduct of clinical trials and the manufacture of products; risks associated with the Company’s inability to enter into partnerships; risks associated with government regulations; the risks associated with the protection of the Company’s intellectual property rights; risks associated with employee issues and growth management; risks associated with ADS and common stock of the Company, risks associated with the pandemic caused by the coronavirus known as COVID-19 and other risks and uncertainties affecting the business operations and financial condition of the Company.
Forward-looking statements are subject to inherent risks and uncertainties beyond the control of the Company which could cause the actual results, performance or achievements of the Company to be materially different from the expected results, performance or achievements expressed or under- understood by these forward-looking statements. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with the Company’s business in general, see the risks described in the section “Business Factors”. risk ”included in the Company’s Form 20-F for the year ended December 31, 2020 and other Company reports filed or submitted to the United States Securities and Exchange Commission (SEC). All forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update them. reasons why actual results could differ materially from those anticipated in forward-looking statements, even if new information becomes available in the future.